Comparing Vical (VICL) & Allena Pharmaceuticals (ALNA)
Vical (NASDAQ:VICL) and Allena Pharmaceuticals (NASDAQ:ALNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.
Insider and Institutional Ownership
46.7% of Vical shares are owned by institutional investors. Comparatively, 84.5% of Allena Pharmaceuticals shares are owned by institutional investors. 4.6% of Vical shares are owned by company insiders. Comparatively, 36.7% of Allena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of recent recommendations for Vical and Allena Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vical presently has a consensus price target of $4.00, indicating a potential upside of 238.98%. Allena Pharmaceuticals has a consensus price target of $29.71, indicating a potential upside of 308.16%. Given Allena Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Allena Pharmaceuticals is more favorable than Vical.
This table compares Vical and Allena Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Vical and Allena Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vical||$1.62 million||15.89||-$16.25 million||($0.81)||-1.46|
|Allena Pharmaceuticals||N/A||N/A||-$35.65 million||($1.72)||-4.23|
Vical has higher revenue and earnings than Allena Pharmaceuticals. Allena Pharmaceuticals is trading at a lower price-to-earnings ratio than Vical, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Vical has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500.
Allena Pharmaceuticals beats Vical on 7 of the 13 factors compared between the two stocks.
Vical Company Profile
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection. Vical Incorporated has a license agreement with Astellas Pharma Inc. to develop and commercialize VL-2397 antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.